<DOC>
	<DOCNO>NCT00479973</DOCNO>
	<brief_summary>Introduction : According World Health Organization ( WHO ) , approximately 150 million people worldwide type 2 diabetes . Common cassia cinnamon report anti-diabetic lipid-lowering effect . Objective : To determine combination common cassia cinnamon product Cinnamonforce™ ( Cinnamomum verum C. aromaticum ) reduce fast blood glucose , insulin , glycosylated hemoglobin ( HA1C ) , triglyceride , total cholesterol , HDL cholesterol LDL cholesterol level people type 2 diabetes . Methodology : Seventy ( 70 ) type 2 diabetic participant randomize receive either 140 mg Cinnamonforce twice daily placebo 12 week . Physical laboratory measurement take baseline , 2 week , 4 week , 8 week end trial , 13 week . Results : The difference measurement obtain group receive Cinnamonforce placebo group analyze discuss .</brief_summary>
	<brief_title>The Anti-Diabetic Cholesterol-Lowering Effects Cinnamon Cassia Bark</brief_title>
	<detailed_description>A randomized placebo-controlled clinical trial conduct evaluate impact Cinnamonforce™ different serum marker relate diabetes lipid management . Cinnamonforce™ proprietary blend Cinnamomum aromaticum Cinnamomum verum bark contain 47 mg hydroethanolic extract ( min . 8 % total phenolic ) 23 mg supercritical extract ( min . 35 % cinnamaldehyde ) per capsule . Based inclusion exclusion criterion outline 13A , seventy ( 70 ) participant randomize use computer-derived random number generator treatment group receive Cinnamonforce™ control group receive placebo . The manufacturer Cinnamonforce™ , New Chapter , generate treatment allocation retain sealed opaque envelope end trial . Patients , investigator , statistician blind end trial . Participants administer 140 mg Cinnamonforce™ twice daily placebo identical size , shape , colour odour . Patients instructed take two capsule ( 140 mg ) end two large meal day 3 month . Compliance assess pill count.Participants ask come assessment predefined time point include : baseline , 2 week , 4 week , 8 week end point ( 13 week ) . At time point , objective subjective measurement obtain . The primary objective measure consist fast blood glucose , insulin HA1C . Secondary biochemical measure include lipid panel ( total cholesterol , triglyceride , HDL LDL ) . Other secondary objective measure consist blood pressure , weight , body mass index ( BMI ) , waist/hip measurement , patient self-monitoring blood glucose homeostasis model assessment insulin resistance ( HOMA-IR ) calculation . Liver kidney toxicity intervention assess serum measurement liver panel ( AST , ALT , total protein , albumin , alkaline phosphatase , total bilirubin direct bilirubin ) , creatinine blood-urea-nitrogen ( BUN ) . Coagulability effect measure ( PT , PTT , fibrinogen ) . Subjective tolerability treatment report adverse effect also include secondary outcome . Another secondary outcome consist subjective score self-reported questionnaire , i.e . Diabetes-39 , SF-36 .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Diagnosed type 2 diabetes Aged &gt; 30 Male female Not take antidiabetic lipidlowering medication OR stable drug regimen least 3 month without planned dosage change participant attend physician Have fast blood glucose 815 mmol/L Not take medication natural health product may affect serum parameter test Having already educate exercise dietary change know improve glucose control Type 1 diabetic Patients take insulin Pregnant plan pregnancy Breastfeeding Known allergy ingredient Cinnamonforce Patients underlying heart , liver , kidney , endocrine neurologic disease Patients unstable hypoglycemic lipidlowering drug regime patient drug regimen less 3 month , patient take medication may affect serum parameter test</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>diabetes</keyword>
	<keyword>non-insulin dependant diabetes</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>cinnamon</keyword>
	<keyword>natural health product</keyword>
	<keyword>hypercholesterolemia</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>elevate cholesterol</keyword>
</DOC>